Mohs surgery

Last updated
Mohs surgery
Mohs ear.jpg
The ear of a 63-year-old man, photographed sixteen days after Mohs surgery to remove a squamous cell carcinoma on the left upper edge of the ear, and three days after removal of the sutures.
MeSH D015580

Mohs surgery, developed in 1938 by a general surgeon, Frederic E. Mohs, is microscopically controlled surgery used to treat both common and rare types of skin cancer. During the surgery, after each removal of tissue and while the patient waits, the tissue is examined for cancer cells. That examination dictates the decision for additional tissue removal. Mohs surgery is the gold standard method for obtaining complete margin control during removal of a skin cancer (complete circumferential peripheral and deep margin assessment - CCPDMA) using frozen section histology. [1] CCPDMA or Mohs surgery allows for the removal of a skin cancer with very narrow surgical margin and a high cure rate.

Contents

The cure rate with Mohs surgery cited by most studies is between 97% and 99.8% for primary basal-cell carcinoma, the most common type of skin cancer. [2] : 13  Mohs procedure is also used for squamous cell carcinoma, but with a lower cure rate. Recurrent basal-cell cancer has a lower cure rate with Mohs surgery, more in the range of 94%. [2] : 7  It has been used in the removal of melanoma-in-situ (cure rate 77% to 98% depending on surgeon), and certain types of melanoma (cure rate 52%). [2] : 4  [3] : 211–20 

Other indications for Mohs surgery include dermatofibrosarcoma protuberans, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, merkel cell carcinoma, Paget's disease of the breast, atypical fibroxanthoma, and leiomyosarcoma. [3] : 193–203  [4] Because the Mohs procedure is micrographically controlled, it provides precise removal of the cancerous tissue, while healthy tissue is spared. Mohs surgery can also be more cost effective than other surgical methods, when considering the cost of surgical removal and separate histopathological analysis. However, Mohs surgery should be reserved for the treatment of skin cancers in anatomic areas where tissue preservation is of utmost importance (face, neck, hands, lower legs, feet, genitals). [4]

Uses

Mohs surgery is most commonly used on the head and neck, where its use conserves normal tissue and decreases the risk of recurrence. For these reasons, it is also considered for skin cancers on hands, feet, ankles, shins, nipples, or genitals. [4] [5] Mohs surgery should not be used on the trunk or extremities for uncomplicated, non-melanoma skin cancer of less than one centimeter in size. [4] [5] On these parts of the body, the risks exceed the benefits of the procedure. [4] [5]

Technique

Divided Mohs Section Quadrants.svg
Divided Mohs Section
Pacman 1 Piece Mohs surgery 1Pacman.svg
Pacman 1 Piece
Double Pacman Mohs surgery 2Pacman.svg
Double Pacman

In 2012, the American Academy of Dermatology published appropriate use criteria (AUC) on Mohs micrographic surgery in collaboration with the following organizations: American College of Mohs Surgery; American Society for Mohs Surgery; and the American Society for Dermatologic Surgery Association. More than 75 physicians contributed to the development of the Mohs surgery AUC, which were published in the Journal of the American Academy of Dermatology and Dermatologic Surgery. [4]

The Australasian College of Dermatologists, in concert with the Australian Mohs Surgery Committee, has also developed evidence based guidelines for Mohs Surgery.[ citation needed ]

The Mohs procedure is a pathology sectioning method that allows for the complete examination of the surgical margin. It is different from the standard bread loafing technique of sectioning, where random samples of the surgical margin are examined. [6] : 112–3  [2] : 3–4  [7]

Mohs surgery is performed in four steps:

The procedure is usually performed in a physician's office under local anesthetic. A small scalpel is utilized to cut around the visible tumor. Unlike a normal surgical excision, a Mohs surgery cut is performed at a beveling between 10 and 45 degrees to allow visibility of all skin layers during pathological diagnosis. [8] A very small surgical margin is utilized, usually with 1 to 1.5 mm of "free margin" or uninvolved skin. The amount of free margin removed is much less than the usual 4 to 6 mm required for the standard excision of skin cancers. [9] After each surgical removal of tissue, the specimen is processed, cut on the cryostat and placed on slides, stained with H&E and then read by the Mohs surgeon/pathologist who examines the sections for cancerous cells. If cancer is found, its location is marked on the map (drawing of the tissue) and the surgeon removes the indicated cancerous tissue from the patient. This procedure is repeated until no further cancer is found. [10] The vast majority of cases are then reconstructed by the Mohs surgeon. Some surgeons utilize 100 micrometres between each section, and some utilize 200 micrometres between the first two sections, and 100 micrometres between subsequent sections (10 crank of tissue set at 6 to 10 micrometre is roughly equal to 100 micrometres if one allows for physical compression due to the blade).

Blood thinners

The trend in skin surgery over the last 10 years has been to continue anticoagulants while performing skin surgery. Most cutaneous bleeding can be controlled with electrocautery, especially bipolar forceps. The benefit gained by ease of hemostasis is weighed against the risk of stopping anticoagulants; and it is generally preferred to continue anticoagulants. [11]

Cure rate

Few specialists dispute the cure rate for Mohs, especially pathologists familiar with the procedure. [6] : 116  Extensive studies performed by Mohs involving thousands of patients with both fixed tissue and fresh tissue cases have been reported in the literature. [12] Other surgeons repeated the studies with also thousands of cases, with nearly the same results. [2] [ page needed ]

Clinical 5 year cure rates with Mohs surgery:

  1. 4085 cases of primary and recurrent cancer of face, scalp, and neck. Cure rate of 96.6%. [12] : 55 
  2. 1065 cases of squamous cell carcinoma of face, scalp, and neck –cure rate 94.8% [12] : 57 
  3. 2075 cases of basal-cell cancer of the nose both primary and recurrent, cure rate 99.1%. [12] : 79 
  4. Cure rate for basal-cell cancer of the ear, less than 1 cm, 124 cases, cure rate 100%. [12] : 101 
  5. Cure rate of basal-cell cancer of the ear, 1 to 2 cm, 170 cases, 100%.[ citation needed ] One needs to keep in mind that the cases performed by Mohs were for large and extensive tumors, often treated numerous times before by other surgeons. Regardless, his cure rate for small primary tumors was either 100% or near 100% when separated from larger or recurrent tumors.

These are only a small number of cases reported by Mohs, and numerous other articles by other authors have shown tremendous cure rates for primary basal-cell carcinoma. Studies by Smeet, et al. showing a Mohs cure rate of about 95%, and another study in Sweden showing Mohs cure rate of about 94%. [13]

Cure rate variation

Some of Mohs' data revealed a cure rate as low as 96%, but these were often very large tumors, previously treated by other modalities. Some authors claim that their 5-year cure rate for primary basal-cell cancer exceeded 99% while other noted more conservative cure rate of 97%. The quoted cure rate for Mohs surgery on previously treated basal-cell cancer is about 94%. [2] : 6–7  Reasons for variations in the cure rate include the following.

  1. Modern frozen section method. Frozen section histology does not give the added margin of safety by the cytotoxic Mohs paste, [14] originally used by Mohs. This paste might have destroyed any residual cancer cells not detected by the pathologist.
  2. Missing epidermal margins. Ideally, the Mohs section should include 100% of the epidermal margin, but greater than 95% is often accepted. [3] : 62  Vigorous scrubbing, poorly controlled initial curettage, poor tissue health, technician's error, and surgeon's error can introduce areas missing epithelial margin. Some surgeons consider 70% epithelial margin acceptable, while others suggest 100% margin. In the ideal situation, 100% of the epithelial margin should be available to be reviewed on serial sectioning of the Mohs specimen.
  3. Misreading of the pathology slide. It is difficult to differentiate between a small island of basal-cell carcinoma and a hair follicle structure. Many Mohs surgeons limit their tissue processing to include only 2 sections of tissue. [2] : 307  This severely hampers their ability to determine if a structure is a hair follicle or a carcinoma. Two histologic sections can not fully distinguish these two nearly identical structures, and can lead to either "false negative" or "false positive" errors by either calling a section clear of tumor, or calling a section positive for tumor, respectively. [6] : 134, 453  Serial sectioning of the tumor is preferred by other surgeons. [3] : 62, 272  Surgeons who perform serial sectioning through the block of tissue (usually 100 micrometres apart) are assured of the contiguous nature of his tumor and the distance of the tumor from the surgical margin, and are familiarized with the nature of the tumor. Serial sectioning also makes it easier to work with three-dimensional tumor with margins that are difficult to compress.
  4. Compression artifact, freezing artifact, cautery artifact, tissue folds, crush artifact from forceps, relaxing incision artifact, cartilage dropping out, fat compression, poor staining, dropping of tumor, etc. [6] : 149–62  These can be introduced as the tumor is "flattened". Stain can run from the surgical edge, and stain the surgical margin – giving a false impression that the entire surgical margin is clear, when it is not. While some surgeons unfamiliar with the "whole piece" or "PacMan" [3] : 86–9  methods of processing might suggest that multiple piece sectioning is better than one, in fact the more tissue sections are cut, the more artifacts in staining and tissue malformation will be introduced. It is imperative that the surgeon be fully familiar with tissue handling and processing; and not simply rely on a trained technologist to perform his sectioning.
  5. Hard-to-see tumor in heavy inflammatory infiltrate. [6] : 446  This can occur with squamous cell carcinoma, especially when complicated with local infection, or intrinsic lymphoproliferative disorders (chronic lymphocytic leukemia). Because of abnormal peripheral blood profile, response to inflammatory skin conditions with patients with myelomonocytic leukemia can have appearance of atypical cells at sites of inflammation, confusing the Mohs surgeon. [6] : 446 
  6. Perineural spread, and benign changes simulating perineural spread. Tumor spreading along a nerve can be difficult to visualize, and sometime benign plasma cells can surround the nerve, simulating cancer. [6] : 446–7 
  7. Anatomical area that is difficult to cut and process. [15] : 16  Examples would be the ear, and other three-dimensional structures like eyelids. The ability to make a scallop shaped incision is increasingly difficult when the surgical surface is no longer a flat plane, but is a three-dimensional rigid structure.
  8. Recurrent skin cancer with multiple islands of recurrence. This can occur with either previous excision, or after electrodesiccation and curettage. As these residual skin cancer are often bound in scar tissue, and present in multiple location in the scar of the previous surgical defect – they are no longer contiguous in nature. Some surgeons advocate the removal of the complete scar in the treatment of "recurrent" skin cancers. Others advocate removing only the island of local recurrence, and leaving the previous surgical scar behind. The decision is often made depending on the location of the tumor, and the goal of the patient and physician.
  9. Unreported or underreported recurrence. Many patients do not return to the original surgeon to report a recurrence. The consulting surgeon on the repeat surgery may not inform the first surgeon of the recurrence. The time it takes for a recurrent tumor to be visible to the patient might be 5 or more years. Quoted "cure" rates must be looked upon with the understanding that a 5-year cure rate might not necessary be correct. As basal-cell carcinoma is a very slowly progressing tumor, a 5-year no recurrence rate might not be adequate. Longer follow up might be needed to detect a slow growing tumor left in the surgical scar.
  10. Poor training of the surgeon/pathologist/histotechnologist. While Mohs surgery is essentially a technical method of tissue handling and processing, the skill and training of the surgeon can greatly affect the outcome. Success requires a foundation of good tissue handling and good surgical skill and hemostasis, based on the tissue processing and staining technique. A surgeon without a good histotechnologist does not have access to sufficiently high quality information about the cancer, and a histotechnologist without a good surgeon can not produce quality slides. Originally, surgeons learned the procedure by spending a few hours to several months with Mohs or during their residencies. [3] : 4  Today, many Mohs surgeons complete a fellowship after their dermatology residency, spending hundreds of hours observing and performing Mohs surgery under careful supervision of highly experienced Mohs surgeons. This is the most comprehensive and thorough method of learning Mohs surgery. Others learn the technique in their dermatology residencies and through courses and preceptorships. It is highly encouraged that a physician interested in learning Mohs surgery should spend extended time observing, cutting, processing, and staining Mohs specimens. It is vital that the histotechnologist prepare high quality slides. The histology block must be correctly mounted, cut, and stained the first time, as there is no second chance in Mohs histology. It is not a procedure that can be properly mastered in a short period of time.

Comparison to other modalities of treatment

Pictogram of CCPDMA or margin controlled histology Margin Controlled Bread Loaf.svg
Pictogram of CCPDMA or margin controlled histology
Pictogram of standard bread loafing histology Bread loafing.svg
Pictogram of standard bread loafing histology
False negative in standard bread loafing histology FalseNegativeBreadLoaf.svg
False negative in standard bread loafing histology
Comparing Mohs Method to Smashing an Aluminum Piepan Smash Pie Pan.svg
Comparing Mohs Method to Smashing an Aluminum Piepan
How a Mohs section is flattened with relaxing incisions Mohsflattening2.svg
How a Mohs section is flattened with relaxing incisions

Mohs surgery is not suitable for all skin cancers. [4]

Mohs micrographic surgery is the most reliable form of margin control; utilising a unique frozen section histology processing technique – allowing for the complete examination of 100% of the surgical margin. The method is unique in that it is a simple way to handle soft, hard-to-cut tissue. It is superior to serial bread loafing at a 0.1 mm interval for improved false negative error rate, requiring less time, tissue handling, and fewer glass slides mounted.

The clinical quotes for cure rate of Mohs surgery are from 97% to 99.8% after 5 years for newly diagnosed basal-cell cancer (BCC), decreasing to 94% or less for recurrent basal-cell cancer. Radiation oncologists quote cure rates from 90 to 95% for BCCs less than 1 or 2 cm, and 85 to 90% for BCCs larger than 1 or 2 cm. The Surgical excision cure rate varies from 90 to 95% for wide margins (4 to 6 mm) and small tumors, to as low as 70% for narrow margins and large tumors.

Society and culture

Some commentators argue that skin cancer surgery, including Mohs surgery, is overutilised as rates of skin cancer surgery are increasing worldwide. It is unclear if this relates to higher rates of skin cancer, increased vigilance in diagnosis, and increased availability of the procedure, or patient and doctor preferences. The incidence of Mohs surgery increased significantly over the decade between 2004 and 2014. In a sample of 100 Mohs surgeries, the total cost ranged from US$474 to US$7,594, with the higher costs for hospital-based complex procedures. In Australia, the direct out of pocket cost to patients may vary from $0 to $4000. When the non-Mohs surgery is performed by multiple doctors including pathologists the costs may be increased further. This is especially true when the cancer is incompletely excised and requires repeat surgery.

History

Originally, Mohs used a chemical paste (an escharotic agent) to cauterize and kill the tissue. It was made of zinc chloride and bloodroot (the root of the plant Sanguinaria canadensis, which contains the alkaloid sanguinarine). The original ingredients were 40.0 g Stibnite, 10.0 g Sanguinaria canadensis, and 34.5 ml of saturated zinc chloride solution. [12] : 3–6 

This paste is similar to black salve or "Hoxsey's paste" (see Hoxsey Therapy), a fraudulent patent medicine, but its usage is different. Hoxsey used the paste for long periods, a harmful practice that was rapidly discredited. [16] Mohs left the paste on the wound only overnight, and the following day, the cancer and surrounding skin would be anesthetized and the cancer removed. The specimen was then excised, and the tissue examined under the microscope. If cancer remained, more paste was applied, and the patient would return the following day. Later, local anesthetic and frozen section histopathology applied to fresh tissue allowed the procedure to be performed the same day, with less tissue destruction, and similar cure rate. [2] : 3–4 

See also

Related Research Articles

<span class="mw-page-title-main">Mastectomy</span> Surgical removal of one or both breasts

Mastectomy is the medical term for the surgical removal of one or both breasts, partially or completely. A mastectomy is usually carried out to treat breast cancer. In some cases, women believed to be at high risk of breast cancer have the operation as a preventive measure. Alternatively, some women can choose to have a wide local excision, also known as a lumpectomy, an operation in which a small volume of breast tissue containing the tumor and a surrounding margin of healthy tissue is removed to conserve the breast. Both mastectomy and lumpectomy are referred to as "local therapies" for breast cancer, targeting the area of the tumor, as opposed to systemic therapies, such as chemotherapy, hormonal therapy, or immunotherapy.

<span class="mw-page-title-main">Skin cancer</span> Medical condition involving uncontrolled growth of skin cells

Skin cancers are cancers that arise from the skin. They are due to the development of abnormal cells that have the ability to invade or spread to other parts of the body. Skin cancer is the most commonly diagnosed form of cancer in humans. There are three main types of skin cancers: basal-cell skin cancer (BCC), squamous-cell skin cancer (SCC) and melanoma. The first two, along with a number of less common skin cancers, are known as nonmelanoma skin cancer (NMSC). Basal-cell cancer grows slowly and can damage the tissue around it but is unlikely to spread to distant areas or result in death. It often appears as a painless raised area of skin that may be shiny with small blood vessels running over it or may present as a raised area with an ulcer. Squamous-cell skin cancer is more likely to spread. It usually presents as a hard lump with a scaly top but may also form an ulcer. Melanomas are the most aggressive. Signs include a mole that has changed in size, shape, color, has irregular edges, has more than one color, is itchy or bleeds.

<span class="mw-page-title-main">Basal-cell carcinoma</span> Most common type of skin cancer

Basal-cell carcinoma (BCC), also known as basal-cell cancer, basalioma or rodent ulcer, is the most common type of skin cancer. It often appears as a painless raised area of skin, which may be shiny with small blood vessels running over it. It may also present as a raised area with ulceration. Basal-cell cancer grows slowly and can damage the tissue around it, but it is unlikely to spread to distant areas or result in death.

<span class="mw-page-title-main">Dermatofibrosarcoma protuberans</span> Medical condition

Dermatofibrosarcoma protuberans (DFSP) is a rare locally aggressive malignant cutaneous soft-tissue sarcoma. DFSP develops in the connective tissue cells in the middle layer of the skin (dermis). Estimates of the overall occurrence of DFSP in the United States are 0.8 to 4.5 cases per million persons per year. In the United States, DFSP accounts for between 1 and 6 percent of all soft-tissue sarcomas and 18 percent of all cutaneous soft-tissue sarcomas. In the Surveillance, Epidemiology and End Results (SEER) tumor registry from 1992 through 2004, DFSP was second only to Kaposi sarcoma.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

<span class="mw-page-title-main">Lentigo maligna</span> Medical condition

Lentigo maligna is where melanocyte cells have become malignant and grow continuously along the stratum basale of the skin, but have not invaded below the epidermis. Lentigo maligna is not the same as lentigo maligna melanoma, as detailed below. It typically progresses very slowly and can remain in a non-invasive form for years.

<span class="mw-page-title-main">Keratoacanthoma</span> Medical condition

Keratoacanthoma (KA) is a common low-grade rapidly-growing skin tumour that is believed to originate from the hair follicle and can resemble squamous cell carcinoma.

<span class="mw-page-title-main">Frozen section procedure</span> Rapid histological sectioning procedure

The frozen section procedure is a pathological laboratory procedure to perform rapid microscopic analysis of a specimen. It is used most often in oncological surgery. The technical name for this procedure is cryosection. The microtome device that cold cuts thin blocks of frozen tissue is called a cryotome.

<span class="mw-page-title-main">Granular cell tumor</span> Medical condition

Granular cell tumor is a tumor that can develop on any skin or mucosal surface, but occurs on the tongue 40% of the time.

<span class="mw-page-title-main">Frederic E. Mohs</span>

Frederic Edward Mohs was an American physician and general surgeon who developed the Mohs micrographic surgery (MMS) technique in 1938 to remove skin cancer lesions while still a medical student at the University of Wisconsin–Madison. The Mohs procedure is considered the best method for treating certain types of skin cancer, because it has very high cure rates for even high-risk lesions, combined with maximal preservation of healthy tissues.

<span class="mw-page-title-main">Resection margin</span>

A resection margin or surgical margin is the margin of apparently non-tumorous tissue around a tumor that has been surgically removed, called "resected", in surgical oncology. The resection is an attempt to remove a cancer tumor so that no portion of the malignant growth extends past the edges or margin of the removed tumor and surrounding tissue. These are retained after the surgery and examined microscopically by a pathologist to see if the margin is indeed free from tumor cells. If cancerous cells are found at the edges the operation is much less likely to achieve the desired results.

<span class="mw-page-title-main">Skin biopsy</span> Removal of skin cells for medical examination

Skin biopsy is a biopsy technique in which a skin lesion is removed to be sent to a pathologist to render a microscopic diagnosis. It is usually done under local anesthetic in a physician's office, and results are often available in 4 to 10 days. It is commonly performed by dermatologists. Skin biopsies are also done by family physicians, internists, surgeons, and other specialties. However, performed incorrectly, and without appropriate clinical information, a pathologist's interpretation of a skin biopsy can be severely limited, and therefore doctors and patients may forgo traditional biopsy techniques and instead choose Mohs surgery.

<span class="mw-page-title-main">Atypical fibroxanthoma</span> Medical condition

Atypical fibroxanthoma (AFX) of the skin is a low-grade malignancy related to malignant fibrous histiocytoma, which it resembles histologically. Atypical fibroxanthoma manifests as a hard, pink or red papule or nodule that grows over the course of several months and may bleed or ulcerate. They typically occur on the head and neck. Atypical fibroxanthoma is usually asymptomatic.

<span class="mw-page-title-main">Sebaceous carcinoma</span> Medical condition

Sebaceous carcinoma, also known as sebaceous gland carcinoma (SGc), sebaceous cell carcinoma, and meibomian gland carcinoma is an uncommon malignant cutaneous tumor. Most are typically about 1.4 cm at presentation. SGc originates from sebaceous glands in the skin and, therefore, may originate anywhere in the body where these glands are found. SGc can be divided into 2 types: periocular and extraocular. The periocular region is rich in sebaceous glands making it a common site of origin. The cause of these lesions in the vast majority of cases is unknown. Occasional cases may be associated with Muir-Torre syndrome. SGc accounts for approximately 0.7% of all skin cancers, and the incidence of SGc is highest in Caucasian, Asian, and Indian populations. Due to the rarity of this tumor and variability in clinical and histological presentation, SGc is often misdiagnosed as an inflammatory condition or a more common neoplasm. SGc is commonly treated with wide local excision or Mohs micrographic surgery, and the relative survival rates at 5 and 10 years are 92.72 and 86.98%, respectively.

Porocarcinoma (PCA) is a rare form of skin cancer that develops in eccrine sweat glands, i.e. the body's widely distributed major type of sweat glands, as opposed to the apocrine sweat glands which are located primarily in the armpits and perineal area. This cancer typically develops in individuals as a single cutaneous tumor in the intraepidermal spiral part of these sweat glands' ducts at or near to where they open on the skin's surface. PCA tumors are classified as one form of the cutaneous adnexal tumors; in a study of 2,205 cases, PCA was the most common (11.8%) form of these tumors.

<span class="mw-page-title-main">Spiradenoma</span> Medical condition

Spiradenomas (SA) are rare, benign cutaneous adnexal tumors that may progress to become their malignant counterparts, i.e. spiradenocarcinomas (SAC). Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. SA and SAC tumors were regarded as eccrine gland tumors and termed eccrine spiradenomas and eccrine spiradenocarcinomas, respectively. However, more recent studies have found them to be hair follicle tumors and commonly term them spiradenomas and spiradenocarcinomas, respectively. Further confusing the situation, SA-like and SAC-like tumors are also 1) manifestations of the inherited disorder, CYLD cutaneous syndrome (CCS), and 2) have repeatedly been confused with an entirely different tumor, adenoid cystic carcinomas of the salivary gland. Here, SA and SAC are strictly defined as sporadic hair follicle tumors that do not include the hereditary CCS spiradenomas and heridtary spiradenocarcinoms of CCS or the adenoid cystic carcinomas.

<span class="mw-page-title-main">Microcystic adnexal carcinoma</span> Medical condition

Microcystic adnexal carcinoma (MAC) is a rare sweat gland cancer, which often appears as a yellow spot or bump in the skin. It usually occurs in the neck or head, although cases have been documented in other areas of the body. Most diagnosis occur past the age of 50. Although considered an invasive cancer, metastasis rarely occurs. If the tumor spreads, it can grow and invade fat, muscles, and other types of tissue. Main treatments are wide local excision or Mohs micrographic surgery, which ensures that most, if not all, cancer cells are removed surgically.

Electrodesiccation and curettage is a medical procedure commonly performed by dermatologists, surgeons and general practitioners for the treatment of basal cell cancers and squamous cell cancers of the skin. It provides desiccation, coagulation/cauterization, and curettage to remove lesions from the skin.

June K. Robinson is an American dermatologist, academic and researcher. She is a Research Professor of Dermatology at Northwestern University’s Feinberg School of Medicine.

<span class="mw-page-title-main">Dermatologic surgical procedure</span>

Dermatologic surgical procedures are treatments aimed at managing a wide range of medically necessary and cosmetic conditions, with a long history dating back to ancient times.

References

  1. ↑ Minton TJ (August 2008). "Contemporary Mohs surgery applications". Current Opinion in Otolaryngology & Head and Neck Surgery. 16 (4): 376–80. doi:10.1097/MOO.0b013e3283079cac. PMID   18626258. S2CID   10668953.
  2. 1 2 3 4 5 6 7 8 Mikhail, George R.; Mohs, Frederic Edward (1991). Mohs micrographic surgery. Philadelphia: W.B. Saunders. p. 13. ISBN   978-0-7216-3415-9.
  3. 1 2 3 4 5 6 Gross, Kenneth Gary; Steinman, Howard K.; Rapini, Ronald P. (1999). Mohs Surgery: Fundamentals and Techniques. Saint Louis: Mosby. ISBN   978-0-323-00012-3.
  4. 1 2 3 4 5 6 7 Ad Hoc Task Force.; et al. (October 2012). "AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery". Journal of the American Academy of Dermatology. 67 (4): 531–50. doi:10.1016/j.jaad.2012.06.009. PMID   22959232.
  5. 1 2 3 American Academy of Dermatology (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation , American Academy of Dermatology , retrieved 5 December 2013
  6. 1 2 3 4 5 6 7 Maloney, Mary E. (1999). Surgical dermatopathology. Malden, Mass: Blackwell Science. ISBN   978-0-86542-299-5.
  7. ↑ Bowen GM, White GL, Gerwels JW (September 2005). "Mohs micrographic surgery". American Family Physician. 72 (5): 845–8. PMID   16156344.
  8. ↑ Tilleman, T.R.; Tilleman, M.M.; Neumann, M.H.A. (1 May 2005). "Minimal bevelling angle in Mohs micrographic surgery cut: a 10 degrees angle is sufficient". British Journal of Dermatology. 152 (5): 1081–1083 – via National Library of Medicine.
  9. ↑ O'Reilly, Susan E.; Knowling, Meg (March 4, 2005). "Basal Cell Carcinoma". Cancer Management Guidelines. BC Cancer Agency. Archived from the original on February 2, 2009.
  10. ↑ "Mohs Surgery". Mayo Clinic. Retrieved 12 May 2020.
  11. ↑ Alcalay J (August 2001). "Cutaneous surgery in patients receiving warfarin therapy". Dermatologic Surgery. 27 (8): 756–8. doi:10.1046/j.1524-4725.2001.01056.x. PMID   11493301. S2CID   43738930.
  12. 1 2 3 4 5 6 Mohs, Frederic Edward (1978). Chemosurgery: microscopically controlled surgery for skin cancer. Springfield, Ill: Thomas. ISBN   978-0-398-03725-3.[ page needed ]
  13. ↑ Wennberg AM, Larkö O, Stenquist B (September 1999). "Five-year results of Mohs' micrographic surgery for aggressive facial basal-cell carcinoma in Sweden". Acta Dermato-Venereologica. 79 (5): 370–2. doi: 10.1080/000155599750010292 . PMID   10494714.
  14. ↑ McDaniel S, Goldman GD (December 2002). "Consequences of using escharotic agents as primary treatment for nonmelanoma skin cancer". Archives of Dermatology. 138 (12): 1593–6. doi: 10.1001/archderm.138.12.1593 . PMID   12472348.
  15. ↑ Mohs, Frederic Edward (1956). Chemosurgery in cancer, gangrene and infections: featuring a new method for the microscopically controlled excision of cancer. Springfield, Ill: Thomas. OCLC   488726321.
  16. ↑ "This Week in FDA History". U.S. Food and Drug Administration. Archived from the original on 8 November 2006. Retrieved 2008-08-27.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.